title: Successful treatment with ceritinib after crizotinib induced hepatitis.
abstract: We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.
authors.affiliation: CHU de Caen, Department of Pharmacology, Caen F-14032, France; Centre François Baclesse, Department of Clinical Research, Caen F-14000, France. Electronic address: marion.sassier@hotmail.fr.
authors.forename: Marion
authors.initials: M
authors.lastname: Sassier
authors.affiliation: CHU Strasbourg, Department of Pneumology, Strasbourg F-67000, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Mennecier
authors.affiliation: CHU Strasbourg, Department of Pneumology, Strasbourg F-67000, France.
authors.forename: Anthony
authors.initials: A
authors.lastname: Gschwend
authors.affiliation: CHU Strasbourg, Department of Pharmacology, Strasbourg F-67000, France.
authors.forename: Mikahl
authors.initials: M
authors.lastname: Rein
authors.affiliation: CHU de Caen, Department of Pharmacology, Caen F-14032, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Coquerel
authors.affiliation: CHU de Caen, Department of Pharmacology, Caen F-14032, France; Normandy University, Department of General Medicine, Caen F-14032, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Humbert
authors.affiliation: CHU de Caen, Department of Pharmacology, Caen F-14032, France.
authors.forename: Joachim
authors.initials: J
authors.lastname: Alexandre
authors.affiliation: CHU de Caen, Department of Pharmacology, Caen F-14032, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Fedrizzi
authors.affiliation: Centre François Baclesse, Department of Oncology, Caen F-14000, France.
authors.forename: Radj
authors.initials: R
authors.lastname: Gervais
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy*; D000077547:Crizotinib; D057915:Drug Substitution; D005260:Female; D006505:Hepatitis / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011743:Pyrimidines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; D013450:Sulfones; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib
keywords: Anaplastic lymphoma kinase (ALK); Ceritinib; Crizotinib; Hepatitis; Non-small-cell-lung-cancer (NSCLC)